The patent covers the antibody molecule, various uses of the antibody, its derivatives, and a method for using it. In addition, the patent protects other similar antibodies also designed to treat cancers such as prostate and breast cancer. Arius revealed it has several additional patent applications pending.
AR7BD-33-11A is one of a series of anti-CD63 antibodies generated through Arius’s proprietary FunctionFirst product platform. Arius has shown that antibodies directed against the CD63 target have a significant impact on cancers such as human pancreatic cancer, melanoma, breast and prostate cancers.
Due to its potency, and other desirable characteristics, AR7BD-33-11A was selected as a lead antibody and humanized to make it suitable for human clinical trials.
“Patents are key to Arius’s commercial success,” said Dr David Young, president and CEO of Arius. “Issued patents also help validate our technology and demonstrate the inventiveness of our science.”